10-K: Inogen Narrows Losses, Boosts Sales Amid Product Expansion

Inogen, Inc. reported a significant reduction in net loss for fiscal year 2025, driven by increased international sales and strategic product portfolio expansion.

Summary

• Net loss decreased by 36.6% to $22.7 million in 2025 from $35.9 million in 2024.
• Total revenue increased by 3.9% to $348.7 million in 2025 from $335.7 million in 2024.
• Sales revenue grew by 5.9% to $295.3 million, primarily attributable to higher demand in international sales.
• Approximately 189,400 oxygen systems were sold during 2025, a 20.3% increase compared to 157,500 systems sold in 2024.
• International sales increased by 18.4% to $138.8 million for the year ended December 31, 2025.
• The Simeox airway clearance system received FDA 510(k) clearance for use in the United States in December 2024.
• In January 2025, Inogen entered into a Strategic Collaboration Agreement with Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (Yuwell), which broadened its product portfolio through distribution of the Inogen Voxi 5 stationary oxygen concentrator and Aurora CPAP masks in the U.S.
• The Board of Directors authorized a share repurchase program of up to $30.0 million on February 20, 2026, set to expire on December 31, 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting significant progress in reducing net losses and expanding the product portfolio through strategic collaborations and new product clearances, despite some declines in rental revenue and U.S. sales.

Positives

• Net loss significantly decreased by 36.6% ($13.1 million decrease) for the year ended December 31, 2025, compared to the prior year.
• Total revenue increased by 3.9% to $348.7 million, indicating overall business growth.
• Sales revenue grew by 5.9% to $295.3 million, primarily driven by strong international demand.
• The company sold approximately 189,400 oxygen systems in 2025, a 20.3% increase year-over-year.
• International sales demonstrated robust growth of 18.4%, highlighting successful global market penetration.
• The Simeox airway clearance system received FDA 510(k) clearance in December 2024, expanding the company's addressable market opportunity in the U.S.
• A strategic collaboration with Yuwell was established in January 2025, broadening the product portfolio with the Inogen Voxi 5 stationary oxygen concentrator and Aurora CPAP masks, and enhancing the innovation pipeline.
• Management and the independent registered public accounting firm concluded that internal control over financial reporting was effective as of December 31, 2025, indicating strong financial governance.
• The Board authorized a $30.0 million share repurchase program, signaling confidence in the company's valuation and commitment to shareholder returns.

Negatives

• Rental revenue decreased by 6.3% ($3.6 million decrease) for the year ended December 31, 2025, primarily due to a higher mix of lower private-payor reimbursement rates and fewer patients on service.
• U.S. sales decreased by 3.1% for the year ended December 31, 2025, compared to the prior year, primarily due to channel mix.
• Gross margin on sales revenue decreased to 44.5% in 2025 from 46.7% in 2024, driven by customer mix and higher cost premiums for semiconductor chips.
• Gross margin on rental revenue decreased to 42.7% in 2025 from 43.3% in 2024, primarily due to a higher mix shift of private-payor reimbursement and lower net revenue per rental patient.
• Net cash used in operating activities was $11.2 million in 2025, a shift from net cash provided of $5.9 million in 2024.
• The company incurred a goodwill impairment charge of $32.9 million in the third quarter of 2023 due to its market capitalization falling below its carrying amount.
• Legal settlement costs increased by $1.8 million in 2025, contributing to general and administrative expenses.
• The stock price experienced significant volatility, trading as high as $12.91 and as low as $5.70 per share during the last twelve months.

Risks

• Intense international, national, regional, and local competition in the respiratory market, including from large, well-capitalized companies with greater resources.
• Dependence on a limited number of customers for a significant portion of sales revenue (top 10 customers accounted for 38.9% of total revenue in 2025).
• Reliance on single-source or limited-source suppliers for key components (e.g., semiconductor chips), which can lead to supply chain disruptions, production delays, and increased costs.
• The need to continuously enhance existing products and develop or acquire new products that respond to customer needs and preferences to maintain competitiveness.
• The complex and lengthy reimbursement process, with significant reliance on Medicare and private payors, and the potential for future reductions in reimbursement rates or changes in payment methodologies.
• Increases in operating costs, particularly labor and raw materials, which may not be offset by price increases due to fixed reimbursement rates.
• Adverse effects on customer and consumer spending, as well as demand for products, due to economic recessions, downturns, periods of inflation, or economic uncertainty.
• Public health crises (e.g., epidemics, pandemics) that can disrupt business activities, supply chains, and prevent employees from conducting business.
• Consolidation in the healthcare industry, leading to pricing pressures and potential loss of customers.
• Healthcare reform measures and legislative changes (e.g., PAYGO Act, changes to the Patient Protection and Affordable Care Act) that could limit government payments for healthcare products and services.
• Potential for manufacturing facilities to become unavailable or inoperable due to natural or man-made disasters, or other manufacturing problems/delays.
• Exposure to the credit and non-payment risk of HME providers, distributors, private label collaborators, and resellers, especially during economic uncertainty.
• Risks associated with international activities, including compliance with anti-bribery laws (e.g., U.S. Foreign Corrupt Practices Act), export controls, economic sanctions, and foreign currency exchange rate fluctuations.
• Potential for substantial warranty or product liability claims, including fire hazards from lithium-ion batteries in POCs.
• Dependence on the services of senior executives and other key technical personnel, with recent turnover in the executive team posing a risk to business continuity and strategy execution.
• Vulnerability to service interruptions, data corruption, cybersecurity risks, data security incidents, and network security breaches, which could disrupt operations, lead to legal liability, or harm reputation.
• Increasing data privacy and data protection regulations (e.g., GDPR, CCPA) that impose costly compliance requirements and potential for increased liability.
• Volatility in the trading price of common stock due to various factors, including quarterly financial variations, competitive announcements, and litigation.
• Challenges in securing and maintaining patent or other intellectual property protection, and the risk of patent and other intellectual property litigation if products infringe on others' rights.
• Potential for fines, penalties, or injunctions if determined to be promoting the use of products for unapproved or off-label uses.
• Risks of fraud, misconduct, or other illegal activity by employees and third parties.
• The implementation of prior authorization rules for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) under Medicare, which could reduce the number of qualified patients or delay service.

Future Outlook

Inogen expects its existing capital resources and cash generated from product sales and rentals to be sufficient to meet operating and investing requirements for at least the next 12 months. The company plans to expand its domestic home medical equipment (HME) network, increase international business-to-business adoption, and improve the productivity of its direct-to-consumer and prescriber sales teams to optimize rental revenues. Significant investment in research and development is planned to develop innovative products and expand clinical evidence. A more extensive launch of the Aurora CPAP masks is scheduled for 2026, and efforts are underway to obtain market feedback and reimbursement coverage for the Simeox product in the U.S. The collaboration with Yuwell is also aimed at accelerating entry into the Chinese market. The company anticipates that private payor reimbursement levels will generally be reset in accordance with Medicare payment amounts, and stationary and non-delivery ambulatory oxygen reimbursement rates are expected to continue to fluctuate.

Management Comments

• "We believe that our oxygen therapy solutions can help patients with chronic respiratory conditions, including patients with COPD."
• "We believe there is an opportunity to grow portable oxygen therapy usage and develop the market further with innovative POCs and other respiratory products to help patients with chronic conditions breathe better and help providers improve patient outcomes."
• "We are committed to ongoing innovation to meet the needs of patients, providers, and our business-to-business partners to manage the respiratory health issues associated with COPD and other chronic conditions."
• "We believe that Simeox can potentially access a large growing airway clearance and bronchiectasis market opportunity in the U.S."
• "We believe the Voxi is a high-quality concentrator that we can offer at a competitive price."
• "Our goal is to design, build, and market respiratory therapy solutions that redefine how home respiratory care is delivered."
• "We continue to believe there is a sizable international market opportunity, particularly in Europe where there is existing oxygen reimbursement for respiratory conditions."
• "We plan to also continue to invest in clinical studies to evaluate expected improvements in clinical, economic and patient reported outcomes associated with the use of our products as part of our efforts to drive payor and prescriber advocacy for our products."
• "We are focused on continuing to build a clinically meaningful pipeline that brings clear value to patients, prescribers, and customers."
• "We believe that our current cash, cash equivalents, and marketable securities and the cash to be generated from expected product sales and rentals will be sufficient to meet our projected operating and investing requirements for at least the next 12 months."

Industry Context

StockSavvy.ai notes that Inogen's strategic expansion into airway clearance (Simeox) and CPAP masks (Aurora) aligns with a broader trend in the respiratory care market towards comprehensive solutions beyond traditional oxygen therapy. The collaboration with Yuwell for distribution and R&D is a smart move to leverage established players and penetrate new markets like China, reflecting industry efforts to globalize and diversify product offerings. The continued pressure on Medicare reimbursement rates and industry consolidation are consistent themes across the durable medical equipment sector, making Inogen's focus on direct-to-consumer rentals a differentiated strategy to capture lifetime patient value.

Comparison to Industry Standards

• The long-term oxygen therapy market is highly competitive, with Inogen competing against manufacturers and distributors such as Rhythm Healthcare, Caire Medical (a subsidiary of NGK Spark Plug Co., Ltd.), Drive DeVilbiss Healthcare, O2 Concepts, React Health, Nidek Medical Products, Precision Medical, 3B Medical, SysMed, Inc., and GCE Healthcare.
• Respironics (a subsidiary of Koninklijke Philips N.V.) announced its exit from the U.S. portable oxygen concentrator market in early 2024, potentially reducing competition for Inogen.
• Inogen's direct-to-consumer rental strategy is unique among POC manufacturers, as major competitors' direct-to-consumer models are currently limited to sales, avoiding the national accreditation and state-by-state licensing requirements and Medicare billing privileges that Inogen handles.
• Medicare reimbursement rates for stationary oxygen (HCPCS E1390) and oxygen generating portable equipment (HCPCS E1392) have fluctuated, with average rates in former Competitive Bidding Areas (CBAs) for E1390 increasing from $73.88 (Jan 2021) to $98.81 (Jan 2026), and in rural areas from $136.84 (Jan 2021) to $177.16 (Jan 2026).
• The Simeox device is marketed in Europe under the transitional provisions of the EU Medical Devices Regulation 2017/745 (MDR), demonstrating compliance with European regulatory standards.
• Inogen's Quality Management system is certified to ISO 13485:2016 by BSI, and its subsidiary Physio-Assist's system is also certified to ISO 13485:2016 by IMQ, indicating adherence to international quality management standards.

Management Changes

Corporate Governance

Legal Proceedings

• The company reached a mutually agreeable settlement with APT Electronics Inc. in August 2025, resolving a lawsuit regarding alleged unpaid services, inventory, and materials from a prior supply arrangement, with a payment of $1.75 million and $668,000 in legal settlement costs.
• The company is currently party to various other legal proceedings and investigations arising in the normal course of business, which are not anticipated to have a material adverse effect.
• A class action securities lawsuit and related derivatives complaints are currently pending against the company, which are being vigorously defended but could be costly and divert management attention.

Stakeholder Impact

• **Shareholders**: Potential for increased value through the newly authorized $30.0 million share repurchase program. However, future equity issuances could dilute existing ownership. Stock price volatility and pending litigation introduce uncertainty.
• **Employees**: The company emphasizes attracting, developing, and retaining highly qualified employees through competitive wages, benefits, tuition reimbursement, and leadership development programs. DEIBA initiatives aim to foster an inclusive workplace. Health and safety programs are in place to minimize workplace incidents.
• **Customers (Patients)**: Patients benefit from innovative portable oxygen concentrators (POCs) designed for mobility and 24/7 oxygen supply. New products like the Simeox airway clearance system and Aurora CPAP masks expand treatment options. Direct-to-consumer sales and rental strategies aim to improve access and support, though potential prior authorization rules could cause delays.
• **Customers (HME Providers, Distributors, Resellers)**: Business partners are offered low total cost of ownership products to help convert to non-delivery POC models. However, Inogen's direct-to-consumer rental strategy could create competition with these providers. Credit and non-payment risks from these partners are a concern.
• **Suppliers/Vendors**: The company relies on a limited number of vendors for key components, exposing it to supply chain disruptions and potential price fluctuations. The company has initiated second-sourcing initiatives to mitigate these risks.
• **Creditors**: Any future debt financing could lead to increased fixed payment obligations and restrictive covenants, impacting the company's financial flexibility.

Next Steps

• A more extensive launch of the Aurora CPAP masks is planned in 2026, with a focus on market development.
• Efforts are underway to introduce the Simeox product into the U.S. market through a limited market release and planned clinical trials to gather further clinical evidence and support reimbursement coverage.
• The company intends to commercialize Simeox through initial product sales, followed by recurring sales of device disposables.
• The collaboration with Yuwell is working to accelerate the entry of Inogen's brand into the Chinese market.
• Medicare accreditation must be renewed annually starting in 2026 when current accreditations expire (current accreditation expires May 2027).
• The 2026 Annual Meeting of Stockholders is scheduled for Wednesday, May 13, 2026.
• The authorized share repurchase program of up to $30.0 million will be active until December 31, 2027, or until the maximum amount is utilized.

Key Dates

Recommendation

Inogen's significant reduction in net loss and growth in total revenue, particularly international sales, are positive indicators. The strategic expansion into new product categories like airway clearance and CPAP masks, coupled with the Yuwell collaboration, positions the company for future growth. The share repurchase program also signals management's confidence. However, the decline in rental revenue, decreased gross margins, and continued reliance on a limited number of suppliers and customers, along with ongoing competitive and reimbursement pressures, present notable headwinds. The stock's historical volatility and pending class action lawsuit also add a layer of uncertainty. Given these mixed signals, a 'hold' recommendation is appropriate, suggesting investors monitor the execution of new strategies and the resolution of existing challenges before making further investment decisions.

Keywords

Oxygen concentrators, Respiratory health, Medical technology, COPD, Portable oxygen, Stationary oxygen, Simeox, Airway clearance, CPAP masks, Obstructive sleep apnea, SEC filing, 10-K, Financial results, Revenue, Net loss, International sales, Yuwell, Collaboration, FDA clearance, Stock repurchase, Healthcare industry, Medical devices, Corporate governance, Risk factors